US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

15.13 -0.28 (-1.82%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Delcath Systems, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host First Quarter 2025 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Analyst Expectations For Delcath Systems's Future ↗
 
Via Benzinga
News headline image
Uncovering Potential: Delcath Systems's Earnings Preview ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Delcath Systems ↗
 
Via Benzinga
News headline image
Beta Bionics Announces Board Appointment of Gerard Michel
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
News headline image
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
From Delcath Systems, Inc.
Via Business Wire
News headline image
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Third Quarter 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups
From Delcath Systems, Inc.
Via Business Wire
News headline image
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics ↗
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road." 
Via Benzinga
News headline image
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >